MARLBOROUGH, Mass.,
Dec. 14, 2015 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company
focused on discovering and developing innovative therapeutics
primarily in the areas of dermatology and ophthalmology, today
announced that the Company's President and CEO, Dr. Geert Cauwenbergh, will present at a leading
investor and partnering conference, the 8th Annual Biotech Showcase
2016, on Monday, January 11, 2016 at
9:30 a.m. PT in San Francisco, California.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
Dr. Cauwenbergh will present a corporate overview that includes
the Company's clinical programs and the multiple business
development opportunities available based on RXi's proprietary
sd-rxRNA® platform and extensive intellectual property
portfolio. The presentation will be webcast and available on
the "Investors" section of the Company's website,
www.rxipharma.com.
About the Biotech Showcase
Biotech Showcase is an investor and networking conference
devoted to providing private and public biotechnology and life
sciences companies with an opportunity to present and meet with
investors and potential strategics in one place during the course
of one of the industry's largest annual healthcare investor
conferences. Investors and biopharmaceutical executives from around
the world gather in San Francisco
during this critical week which is widely viewed as setting the
tone for the coming year.
Biotech Showcase delegates include investors in private and
public companies, sector analysts, bankers and industry
professionals, as well as biopharmaceutical and life science
company executives. The meeting will be held January
11–13, 2016 in San Francisco,
CA at the Parc 55, San Francisco,
California.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering and developing
innovative therapeutics primarily in the areas of dermatology and
ophthalmology that address high-unmet medical needs. Our discovery
and clinical development programs are based on siRNA technology as
well as immunotherapy agents. These compounds include, but are not
limited to, our proprietary, self-delivering RNAi (sd-rxRNA®)
compounds for the treatment of dermal and ocular scar formation. It
also includes an immunomodulator, Samcyprone™, a proprietary
topical formulation of diphenylcyclopropenone (DPCP), for the
treatment of disorders such as warts, alopecia areata,
non-malignant skin tumors and cutaneous metastases of melanoma.
Building on the pioneering work of RXi's Scientific Advisory
Board Chairman and Nobel Laureate Dr. Craig
Mello, the Company's first RNAi product candidate, RXI-109
(an sd-rxRNA compound) is the Company's first clinical development
candidate. RXI-109 silences Connective Tissue Growth Factor (CTGF),
which plays a key role in tissue regeneration and repair and is
initially being developed to reduce or inhibit scar formation in
the skin and in the eye. RXI-109 is currently being evaluated in
Phase 2a clinical trials in dermatology and a Phase 1/2 trial in
ophthalmology.
RXi's robust pipeline, coupled with an extensive patent
portfolio, provides for product and business development
opportunities across a broad spectrum of therapeutic areas. We are
committed to being a partner of choice for academia, small
companies, and large multinationals. We welcome ideas and proposals
for strategic alliances, including in- and out-licensing
opportunities, to advance and further develop strategic areas of
interest. Additional information may be found on the Company's
website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-8th-annual-biotech-showcase-2016-300192140.html
SOURCE RXi Pharmaceuticals Corporation